Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Dual GIP/GLP-1 Receptor Agonist Tirzepatide for Obesity (BMI>30)

Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects.

Official registry: https://clinicaltrials.gov/study/NCT07777575 · Technical University of Munich · enrollment listed as 150

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Dual GIP/GLP-1 Receptor Agonist Tirzepatide, or Resistance Training. The registry lists allocation as randomized. Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment.

They plan to enroll about 150 people at München. Taking part typically means taking a study drug (or dummy pill), following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment With the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults With Obesity

Interventions: Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance Training

Primary outcome (registry wording): Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 60 Years
  • Are ≥ 18 years and ≤ 60 years of age
  • Have a body mass index (body-mass index (BMI)) of ≥ 30 kg/m2
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
  • In the investigator's opinion, are well motivated, capable, and willing to
  • learn how to self-inject the investigational medicinal product (IMP), as required for this protocol
  • inject the IMP, and
  • comply with trial procedures for the duration of the trial, including adherence to scheduled visits, the prescribed resistance training program (if assigned to the experimental group), lifestyle recommendations, and other requirements as specified in the protocol

Public study contact (from the registry)

Stephan Mueller-Stegner, Dr rer nat

+49 (0)89 289-24494

stephan.mueller@mri.tum.de

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07777575 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07777575?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07777575?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary